Drug name - Varubi

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178550 TERSERA Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Apr, 2027

(4 years from now)

US7049320 TERSERA NK1 antagonists
Aug, 2028

(5 years from now)

CN1606545A TERSERA Pyrrolidine And Piperidine Derivatives As Nk1 Antagonists
Nov, 2020

(1 year, 9 months ago)

CN1606545B TERSERA Pyrrolidine And Piperidine Derivatives As Nk1 Antagonist
Nov, 2020

(1 year, 9 months ago)

CN102276606B TERSERA Hydrochloride Salts Of 8-[{1-(3,5-Bis-(Trifluoromethyl) Phenyl) -Ethoxy}-Methyl] -8-Phenyl-1,7-Diaza-Spiro[4.5] Decan-2-One And Preparation Process Therefor
Mar, 2021

(1 year, 6 months ago)

CN102276606A TERSERA Hydrochloride Salts Of 8-[{1-(3,5-Bis-(Trifluoromethyl) Phenyl) -Ethoxy}-Methyl] -8-Phenyl-1,7-Diaza-Spiro[4.5] Decan-2-One And Preparation Process Therefor
Mar, 2021

(1 year, 6 months ago)

CN101437821B TERSERA Hydrochloride Salts Of 8-[{1-(3,5-Bis-(Trifluoromethyl) Phenyl) -Ethoxy}-Methyl] -8-Phenyl-1,7-Diaza-Spiro[4.5] Decan-2-One And Preparation Process Therefor
Mar, 2021

(1 year, 6 months ago)

CN101437821A TERSERA Hydrochloride Salts Of 8-[{1-(3,5-Bis-(Trifluoromethyl) Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One And Preparation Process Thereof
Mar, 2021

(1 year, 6 months ago)

IN200401329P4 TERSERA Pyrrolidine And Piperidine Derivatives Of General Formula I
Dec, 2022

(2 months from now)

IN218814B TERSERA Pyrrolidine And Piperidine Derivatives Of General Formula I
Dec, 2022

(2 months from now)

EP2004646B1 TERSERA Hydrochloride Salt Of 8-[{1-(3,5-Bis-(Trifluoromethyl) Phenyl) -Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One And Preparation Process Therefor
Aug, 2020

(2 years ago)

EP2004646A2 TERSERA Hydrochloride Salt Of 8-[{1-(3,5-Bis-(Trifluoromethyl) Phenyl) -Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One And Preparation Process Therefor
Aug, 2020

(2 years ago)

EP1882686A2 TERSERA Pyrrolidine And Piperidine Derivates As Nk1 Antagonists
Dec, 2022

(2 months from now)

EP1882686A3 TERSERA Pyrrolidine And Piperidine Derivates As Nk1 Antagonists
Dec, 2022

(2 months from now)

EP1882686B1 TERSERA Pyrrolidine And Piperidine Derivates As Nk1 Antagonists
Dec, 2022

(2 months from now)

EP1463716A1 TERSERA Pyrrolidine And Piperidine Derivates As Nk1 Antagonists
Dec, 2022

(2 months from now)

EP1463716B1 TERSERA Pyrrolidine And Piperidine Derivates As Nk1 Antagonists
Dec, 2022

(2 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796299 TERSERA NK1 antagonists Dec, 2022

(2 months from now)

US7981905 TERSERA Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Apr, 2027

(4 years from now)

US8404702 TERSERA Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Apr, 2027

(4 years from now)

US7563801 TERSERA Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Apr, 2027

(4 years from now)

US8470842 TERSERA Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor Jan, 2029

(6 years from now)

US8361500 TERSERA Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom Oct, 2029

(7 years from now)

US9101615 TERSERA Intravenous formulations of neurokinin-1 antagonists Jul, 2032

(9 years from now)

Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient

Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 90MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.